Tscan Therapeutics Inc (TCRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.89M
Last updated: Nov 17, 2026 at 11:05 AM ET
Tscan Therapeutics Inc (TCRX) Stock Forecast
Analysts expect Tscan Therapeutics (TCRX) to earn -$0.79 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.22M. Of 5 analysts, 1 rates the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.58.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.80, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 20% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 1 | 20.0% |
| Hold | 4 | 80.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 48.1%.
- Fiscal year ending Dec 31, 2026
- -$0.79
- EPS consensus, revenue $3.22M
- Fiscal year ending Dec 31, 2027
- -$0.58
- EPS consensus, revenue $1.67M
- Next report
- Mar 2, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.79 | -$0.89 to -$0.62 | 4 | $3.22M | $2.03M to $5.00M | 3 |
| Dec 31, 2027 | -$0.58 | -$1.03 to -$0.27 | 4 | $1.67M | N/A | 3 |
Quarterly Estimates
The EPS consensus falls from -$0.17 for the quarter ending Dec 31, 2026 to -$0.19 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.17 | -$0.21 to -$0.09 | 6 | $606900 | N/A | 6 |
| Mar 31, 2027 | -$0.19 | -$0.26 to -$0.11 | 2 | $433330 | N/A | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 4 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.87.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.79 | -$0.78 | -$0.78 | -$0.78 | -$0.87 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.58 | -$0.57 | -$0.57 | -$0.57 | -$0.94 | N/A |
| Quarter ending Mar 31, 2027 | -$0.19 | -$0.25 | -$0.24 | -$0.24 | -$0.24 | N/A |
Frequently Asked Questions About TCRX
What is the TCRX stock forecast?
Consensus analyst estimates put Tscan Therapeutics's EPS at -$0.79 for the fiscal year ending Dec 31, 2026, on revenue of $3.22M. The consensus rating from 5 analysts is Hold.
How do analysts rate TCRX stock?
Of 5 analysts covering Tscan Therapeutics, 0 rate it Strong Buy, 1 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from TCRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.79, with estimates from -$0.89 to -$0.62 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.58, with estimates from -$1.03 to -$0.27 from 4 analysts.
What revenue do analysts expect from Tscan Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.22M, with estimates from $2.03M to $5.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.67M.
How many analysts cover TCRX?
5 analysts rate Tscan Therapeutics stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TCRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors